ReviewFrontiers in immunology2025
Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastric metastasis from colorectal cancer: an updated comprehensive review of epidemiology, mechanisms, diagnosis, and management.Frontiers in oncology · 2026Review
- Organ-specific pre-metastatic and metastatic niches in colorectal cancer: "discrepancy in response to immune checkpoint inhibitors in liver and lung metastasis".Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), characterized by high incidence and mortality rates, is an aggressive malignancy that significantly burdens public health. Metastasis represents the principal factor contributing to treatment failure in CRC patients, largely due to limited comprehension of the underlying mechanisms governing this phenomenon. CRC metastasis involves multiple factors, including dynamics within the tumor microenvironment (TME), epithelial-mesenchymal transition (EMT), and the dissemination of cancer cells through the circulatory and lymphatic systems. These mechanisms are regulated by complex molecular interactions. A deeper understanding of the metastatic processes and the identification of viable therapeutic targets could substantially advance innovative clinical interventions. This review highlights key contributors to CRC metastasis, integrates relevant molecular mechanisms with distinct patterns of organ-specific spread, and emphasizes the latest advancements in this field. Additionally, it explores experimental models of CRC and metastasis, provides mechanistic insights, and addresses challenges in the clinical management of metastatic CRC. This article aims to facilitate future research and highlight promising therapeutic opportunities for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.